Announcements Trials
Browse Landscape

Phase

Phase 1 1

Status

Unknown 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Other hematologic neoplasm 1Lymphoid 1

Conditions

Precursor Cell Lymphoblastic Leukemia-Lymphoma 8Leukemia, Myelogenous, Chronic, BCR-ABL Positive 6Leukemia, Myeloid, Chronic-Phase 5Precursor B-Cell Lymphoblastic Leukemia-Lymphoma 1Philadelphia Chromosome 1Myeloproliferative Disorders 1Leukemia, Myeloid, Acute 1Leukemia, Myeloid, Accelerated Phase 1Leukemia 1Gastrointestinal Stromal Tumors 1GIST 1

Interventions

Cyclophosphamide 346Cytarabine 282fludarabine phosphate 203Methotrexate 186Filgrastim 159Busulfan 148Etoposide 135Peripheral Blood Stem Cell Transplantation 134fludarabine 128Rituximab 119Radiotherapy 111Vincristine 102Cyclosporine 98Daunorubicin 96Antilymphocyte Serum 94Dexamethasone 91Tacrolimus 86Mycophenolic Acid 86Whole-Body Irradiation 81Melphalan 79Imatinib Mesylate 69Idarubicin 67Granulocyte Colony-Stimulating Factor 66Mercaptopurine 65Azacitidine 65Methylprednisolone 59Doxorubicin 58Prednisone 57Clofarabine 54sargramostim 53

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Leukemia × olverembatinib × Clear all
NCT05495035 2023-03-02

Study for Safety and Efficacy of Olverembatinib Combined With APG-2575 in Children With Relapsed/Refractory Ph + ALL

Institute of Hematology & Blood Diseases Hospital, China

Phase 1 Unknown
22 enrolled
LymphoidOther hematologic neoplasm

Leukemia, Precursor Cell Lymphoblastic Leukemia-Lymphoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡